Pulmonary/Respiratory Diseases | Preclinical Developments | UNITED STATES

CohBar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

CohBar’s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

Lead Product(s): MBT2

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 01, 2020

Details:

CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).

CohBar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides

Lead Product(s): MBT2

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).

SutroVax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Lead Product(s): SVX-24

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $110.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing March 26, 2020

Details:

SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.

Forge Therapeutics, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $190.5 million Upfront Cash: Undisclosed

Deal Type: Collaboration March 25, 2020

Details:

Under this agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes. Forge will retain control of the programme prior to Roche exercising its option.

Hepion Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study

Lead Product(s): CRV431

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2020

Details:

The goal of the study was to determine if the anti-fibrotic activity of CRV431, which has been previously observed in many experimental models of liver disease.

Medicinova

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

MediciNova Announces Plans to Develop MN-166 (ibudilast)

Lead Product(s): Ibudilast

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2020

Details:

MediciNova’s decision to pursue development of this indication was based on positive results of a recent preclinical study in an animal model of ARDS.

Altavant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavan...

Lead Product(s): OSP-101

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Altavant Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 08, 2020

Details:

This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration.

Airway Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent...

Lead Product(s): AT-100

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $15.5 million Upfront Cash: Undisclosed

Deal Type: Series C Financing January 08, 2020

Details:

This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

CohBar

CohBar’s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

CohBar

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides

SutroVax

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Forge Therapeutics, Inc

Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic

Hepion Pharmaceuticals

Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study

Medicinova

MediciNova Announces Plans to Develop MN-166 (ibudilast)

Altavant Sciences

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavan...

Airway Therapeutics

Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent...